Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Equity Average (2016 - 2025)

Historic Equity Average for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to $103.8 million.

  • Coherus Oncology's Equity Average rose 22064.14% to $103.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.8 million, marking a year-over-year increase of 22064.14%. This contributed to the annual value of -$162.7 million for FY2024, which is 164.07% up from last year.
  • As of Q3 2025, Coherus Oncology's Equity Average stood at $103.8 million, which was up 22064.14% from -$31.8 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Equity Average peaked at $204.3 million during Q1 2021, and registered a low of -$185.6 million during Q2 2023.
  • Its 5-year average for Equity Average is -$36.6 million, with a median of -$83.0 million in 2024.
  • Its Equity Average has fluctuated over the past 5 years, first plummeted by 358836.68% in 2023, then surged by 22064.14% in 2025.
  • Over the past 5 years, Coherus Oncology's Equity Average (Quarter) stood at $114.2 million in 2021, then plummeted by 202.65% to -$117.3 million in 2022, then tumbled by 39.43% to -$163.5 million in 2023, then surged by 32.74% to -$110.0 million in 2024, then soared by 194.38% to $103.8 million in 2025.
  • Its Equity Average was $103.8 million in Q3 2025, compared to -$31.8 million in Q2 2025 and -$157.7 million in Q1 2025.